Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.62 |
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 10/20 | 0.59 |
| ▸ | CACNB1 | Q02641 | 10/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.59 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5079974 | 0.83 | CACNA2D1 (0.58) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL8268617 | 0.83 | SIGMAR1 (0.69) | CHRM3CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5026283 | 0.82 | CACNA2D1 (0.58) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL26330969 | 0.81 | CACNA2D1 (0.81) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL6709184 | 0.81 | HSD11B1 (0.69) | CHRM3KCNH2 | |
| SCHEMBL9292241 | 0.81 | CHRM3 (0.67) | CHRM3PKMDRD3KCNH2 | |
| SCHEMBL8268615 | 0.80 | CACNA2D1 (0.71) | CACNA2D1CACNA1BCACNB1CACNA1CCACNA1H | |
| SCHEMBL28015716 | 0.78 | CHRM3 (0.58) | CHRM3PKMDRD3KCNH2 | |
| SCHEMBL10723980 | 0.78 | SIGMAR1 (0.70) | CHRM3DRD3KCNH2 | |
| SCHEMBL10724043 | 0.78 | SIGMAR1 (0.70) | CHRM3DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670775-A4 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2009-04-22 | — | — | EP | claimed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | claimed |
| JP-2007504174-A | — | — | 2007-03-01 | — | — | JP | claimed |
| EP-1670775-A1 | PIPERAZINE SUBTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-06-21 | — | — | EP | claimed |
| WO-2005021523-A1 | PIPERAZINE SUBSTITUTED COMPOUNDS USED AS CALCIUM CHANNEL BLOCKERS | NEUROMED TECHNOLOGIES, INC. (CA) | 2005-03-10 | — | — | WO | claimed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | claimed |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-12-04 | — | — | US | disclosed |
| EP-1871372-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| US-7186726-B2 | Preferentially substituted calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-03-06 | — | — | US | disclosed |
| WO-2006105670-A1 | COMBINATION THERAPY COMPRISING AN N-TYPE CALCIUM CHANNEL BLOCKER FOR THE ALLEVIATION OF PAIN | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147529-A1 | Preferentially substituted calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | CHRM3 346/4885CACNA2D1 36/4885CACNA1B 1/4885 |
| US-20080300262-A1 | Combination Therapy for Relief of Pain | CACNA1B, TRPV1, ORAI1 | CHRM3 300/4885CACNA2D1 90/4885CACNA1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.